表紙
市場調査レポート

肝硬変のパイプライン製品分析

Cirrhosis - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 192530
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
肝硬変のパイプライン製品分析 Cirrhosis - Pipeline Review, H2 2014
出版日: 2014年07月15日 ページ情報: 英文 67 Pages
概要

肝硬変とは、肝臓の一部に付加逆性の瘢痕が生じるという、肝臓の異常状態のことを指します。主な原因として、持続的なアルコール過剰摂取や、ウイルス性B型・B型肝炎、脂肪肝疾患などが挙げられますが、この他にも様々な原因が考えられます。主な徴候には、上腹部の皮膚に毛細血管が見えてくることや、倦怠感、不眠症、皮膚の痒み、食欲不振、体重減少、吐き気、肝臓周辺の疼痛や圧痛、手のひらが赤く染みだらけになること、脱力感などがあります。

当レポートでは、世界各国での肝硬変治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

肝硬変の概要

治療薬の開発

  • 肝硬変向けパイプライン製品:概要
  • 肝硬変向けパイプライン製品:比較分析

各企業で開発中の肝硬変治療薬

大学/研究機関で研究中の肝硬変治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階にある製品

肝硬変治療薬:開発中の製品の一覧(企業別)

肝硬変治療薬:研究中の製品の一覧(大学/研究機関別)

肝硬変治療薬の開発に従事している企業

  • Gilead Sciences, Inc
  • Novartis AG
  • Hyperion Therapeutics, Inc.
  • Intercept Pharmaceuticals, Inc.
  • PharmaIN Corporation
  • Alfact Innovation

肝硬変:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • オルニチンフェニル酢酸塩
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • グリセロールフェニル酪酸
  • obeticholic acid
  • simtuzumab
  • Stem Cell Therapy for Gastrointestinal, CNS and
  • Endocrine and Metabolic Disorders
  • erismodegib
  • ALF-5755
  • PGCベースナトリウム利尿ペプチド

肝硬変治療薬:パイプライン製品の最新動向

肝硬変治療薬:開発が休止状態の製品

肝硬変関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全7件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5288IDB

Summary

Global Markets Direct's, 'Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Cirrhosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cirrhosis Overview
  • Therapeutics Development
    • Pipeline Products for Cirrhosis - Overview
    • Pipeline Products for Cirrhosis - Comparative Analysis
  • Cirrhosis - Therapeutics under Development by Companies
  • Cirrhosis - Therapeutics under Investigation by Universities/Institutes
  • Cirrhosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cirrhosis - Products under Development by Companies
  • Cirrhosis - Products under Investigation by Universities/Institutes
  • Cirrhosis - Companies Involved in Therapeutics Development
    • Gilead Sciences, Inc.
    • Novartis AG
    • Ocera Therapeutics, Inc.
    • Hyperion Therapeutics, Inc.
    • Intercept Pharmaceuticals, Inc.
    • PharmaIN Corporation
    • Alfact Innovation
  • Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glycerol phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • simtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • erismodegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALF-5755 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGC Based Natriuretic Peptides - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cirrhosis - Recent Pipeline Updates
  • Cirrhosis - Dormant Projects
  • Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting
      • Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan
      • Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
      • May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
      • Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD
      • Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD
      • Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cirrhosis, H2 2014
  • Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014
  • Cirrhosis - Pipeline by Novartis AG, H2 2014
  • Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2014
  • Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H2 2014
  • Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014
  • Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014
  • Cirrhosis - Pipeline by Alfact Innovation, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Cirrhosis - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Cirrhosis, H2 2014
  • Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top